A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
← catalyst calendarNCT07613294 · readout ≤ 1,230 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
252estimated
Sites
58
Countries
Australia, Czechia, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-01 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atherosclerosis
- Cardiovascular Diseases
- Lipoprotein(a)
Interventions
- Drug: Lepodisiran — also filed as LY3819469
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in Noncalcified Plaque (NCP) Volume
measured Baseline, Week 104
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed